{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:40Z","timestamp":1794255880282,"version":"4.9.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12325-026-03725-x","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:03:29Z","timestamp":1787367809000},"page":"5031-5046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion"],"prefix":"10.1007","volume":"43","author":[{"given":"Dale","family":"Shepard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M.","family":"Bernthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"3725_CR1","unstructured":"de Saint Aubain Somerhausen J, van de Rijn M. Tenosynovial giant cell tumour. In: WHO Classification of Tumours Editorial Board, editor. WHO classification of tumour series: soft tissue and bone tumours 5th ed., vol. 3. 2020."},{"key":"3725_CR2","unstructured":"National Organization for Rare Disorders. Tenosynovial giant cell tumor. 2023 [cited 2024 Jun 18]. https:\/\/rarediseases.org\/rare-diseases\/tenosynovial-giant-cell-tumor\/."},{"key":"3725_CR3","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","volume":"88","author":"MJL Mastboom","year":"2017","unstructured":"Mastboom MJL, Verspoor FGM, Verschoor AJ, Uittenbogaard D, Nemeth B, Mastboom WJB, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop. 2017;88:688\u201394.","journal-title":"Acta Orthop"},{"key":"3725_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102491","volume":"112","author":"S Stacchiotti","year":"2023","unstructured":"Stacchiotti S, D\u00fcrr HR, Schaefer I-M, Woertler K, Haas R, Trama A, et al. Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. Cancer Treat Rev. 2023;112:102491.","journal-title":"Cancer Treat Rev"},{"key":"3725_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/gcc.2870040312","volume":"4","author":"JA Fletcher","year":"1992","unstructured":"Fletcher JA, Henkle C, Atkins L, Rosenberg AE, Morton CC. Trisomy 5 and trisomy 7 are nonrandom aberrations in pigmented villonodular synovitis: confirmation of trisomy 7 in uncultured cells. Genes Chromosomes Cancer. 1992;4:264\u20136.","journal-title":"Genes Chromosomes Cancer"},{"key":"3725_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/14728222.2022.2067040","volume":"26","author":"G Spierenburg","year":"2022","unstructured":"Spierenburg G, van der Heijden L, van Langevelde K, Szuhai K, Bov\u00e9e JVGM, van de Sande MAJ, et al. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches. Expert Opin Ther Targets. 2022;26:333\u201345.","journal-title":"Expert Opin Ther Targets"},{"key":"3725_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.820046","volume":"13","author":"M Robert","year":"2022","unstructured":"Robert M, Farese H, Miossec P. Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features. Front Immunol. 2022;13:820046.","journal-title":"Front Immunol"},{"key":"3725_CR8","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1080\/14796694.2025.2520744","volume":"21","author":"M van de Sande","year":"2025","unstructured":"van de Sande M, Blay J-Y, Tap W, Lee M, Kaiser E, Beaver S, et al. The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review. Future Oncol. 2025;21:2385\u2013400.","journal-title":"Future Oncol"},{"key":"3725_CR9","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3899\/jrheum.160816","volume":"44","author":"V Ehrenstein","year":"2017","unstructured":"Ehrenstein V, Andersen SL, Qazi I, Sankar N, Pedersen AB, Sikorski R, et al. Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark. J Rheumatol. 2017;44:1476\u201383.","journal-title":"J Rheumatol"},{"key":"3725_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01820-6","volume":"16","author":"NM Bernthal","year":"2021","unstructured":"Bernthal NM, Spierenburg G, Healey JH, Palmerini E, Bauer S, TOPP Study Group, et al. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. Orphanet J Rare Dis. 2021;16:191.","journal-title":"Orphanet J Rare Dis"},{"key":"3725_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020402","volume":"16","author":"WS Choi","year":"2024","unstructured":"Choi WS, Lee SK, Kim J-Y, Kim Y. Diffuse-type tenosynovial giant cell tumor: what are the important findings on the initial and follow-up MRI? Cancers (Basel). 2024;16:402.","journal-title":"Cancers (Basel)"},{"key":"3725_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/OTT.S345878","volume":"15","author":"A Vaynrub","year":"2022","unstructured":"Vaynrub A, Healey JH, Tap W, Vaynrub M. Pexidartinib in the management of advanced tenosynovial giant cell tumor: focus on patient selection and special considerations. Onco Targets Ther. 2022;15:53\u201366.","journal-title":"Onco Targets Ther"},{"key":"3725_CR13","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1080\/14796694.2025.2488635","volume":"21","author":"S Stern","year":"2025","unstructured":"Stern S, McKenzie PF, Bernthal N, O\u2019Neill S, Palmerini E, Randall RL, et al. Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry. Future Oncol. 2025;21:1501\u201310.","journal-title":"Future Oncol"},{"key":"3725_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13244-023-01367-z","volume":"14","author":"G Spierenburg","year":"2023","unstructured":"Spierenburg G, Suevos Ballesteros C, Stoel BC, Navas Ca\u00f1ete A, Gelderblom H, van de Sande MAJ, et al. MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment. Insights Imaging. 2023;14:22.","journal-title":"Insights Imaging"},{"key":"3725_CR15","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/futurepharmacol3040056","volume":"3","author":"A Stamatiou","year":"2023","unstructured":"Stamatiou A, Nguyen-Ngoc T, Wetterwald L, Dolcan A-M, Dei Tos G, Cherix S, et al. Overview of pharmacological therapies for diffuse tenosynovial giant cell tumor. Future Pharmacol. 2023;3:926\u201337.","journal-title":"Future Pharmacol"},{"key":"3725_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clinthera.2016.03.008","volume":"38","author":"HL Gelhorn","year":"2016","unstructured":"Gelhorn HL, Tong S, McQuarrie K, Vernon C, Hanlon J, Maclaine G, et al. Patient-reported symptoms of tenosynovial giant cell tumors. Clin Ther. 2016;38:778\u201393.","journal-title":"Clin Ther"},{"key":"3725_CR17","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.radcr.2022.02.073","volume":"17","author":"AG Christanto","year":"2022","unstructured":"Christanto AG, Kuntara A. Tenosynovial giant cell tumor, localized type, with recurrence, and lung metastases: a case report. Radiol Case Rep. 2022;17:1946\u201350.","journal-title":"Radiol Case Rep"},{"key":"3725_CR18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s11912-025-01679-x","volume":"27","author":"E Palmerini","year":"2025","unstructured":"Palmerini E, Trent JC, Hornicek FJ. Medical management of tenosynovial giant cell tumor. Curr Oncol Rep. 2025;27:844\u201355.","journal-title":"Curr Oncol Rep"},{"key":"3725_CR19","doi-asserted-by":"publisher","first-page":"10521","DOI":"10.1200\/jco.2015.33.15_suppl.10521","volume":"33","author":"H Gelhorn","year":"2015","unstructured":"Gelhorn H, Tong S, Maclaine G, Healey JH, Bukata SV, Keedy VL, et al. Patient-reported outcome instruments meaningful and relevant for tenosynovial giant cell tumor (TGCT): a qualitative study. J Clin Oncol. 2015;33:10521.","journal-title":"J Clin Oncol"},{"key":"3725_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s41687-020-00217-6","volume":"4","author":"RM Speck","year":"2020","unstructured":"Speck RM, Ye X, Bernthal NM, Gelhorn HL. Psychometric properties of a custom Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form and worst stiffness numeric rating scale in tenosynovial giant cell tumors. J Patient Rep Outcomes. 2020;4:61.","journal-title":"J Patient Rep Outcomes"},{"key":"3725_CR21","unstructured":"Xu H, Zhou Y, Li B, Xie X, Du X, Chen B, et al. (P169) Updated efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): 1-year follow-up from Phase 1b. Connective Tissue Oncology Society (CTOS) Annual Meeting. 2023. p. Poster 169."},{"key":"3725_CR22","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay J-Y, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394:478\u201387.","journal-title":"Lancet"},{"key":"3725_CR23","unstructured":"US Food and Drug Administration. Turalio\u00ae (pexidartinib). US Prescribing Information. 2022 [cited 2024 Nov 7]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/211810s009lbl.pdf."},{"key":"3725_CR24","unstructured":"European Medicines Agency. Turalio Assessment Report. 2020 [cited 2025 Sep 18]. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/turalio-epar-refusal-public-assessment-report_en.pdf-0."},{"key":"3725_CR25","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","volume":"403","author":"H Gelderblom","year":"2024","unstructured":"Gelderblom H, Bhadri V, Stacchiotti S, Bauer S, Wagner AJ, van de Sande M, et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403:2709\u201319.","journal-title":"Lancet"},{"key":"3725_CR26","doi-asserted-by":"publisher","first-page":"11558","DOI":"10.1200\/JCO.2025.43.16_suppl.11558","volume":"43","author":"VA Bhadri","year":"2025","unstructured":"Bhadri VA, Gelderblom H, Stacchiotti S, Bauer S, Wagner AJ, van de Sande M, et al. Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial. J Clin Oncol. 2025;43:11558.","journal-title":"J Clin Oncol"},{"key":"3725_CR27","doi-asserted-by":"publisher","first-page":"S1342","DOI":"10.1016\/j.annonc.2025.08.3305","volume":"36","author":"S Bauer","year":"2025","unstructured":"Bauer S, Bhadri VA, Gelderblom H, Stacchiotti S, Wagner AJ, Van de Sande M, et al. 2694P - Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial. Ann Oncol. 2025;36:S1342\u20133.","journal-title":"Ann Oncol"},{"key":"3725_CR28","unstructured":"US Food and Drug Administration. FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor. 2025 [cited 2025 Sep 18]. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-vimseltinib-symptomatic-tenosynovial-giant-cell-tumor."},{"key":"3725_CR29","unstructured":"European Medicines Agency. Vimseltinib. Summary of opinion (initial authorisation). 2025 [cited 2025 Sep 18]. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-romvimza_en.pdf."},{"key":"3725_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1200\/JCO.2022.40.28_suppl.056","volume":"40","author":"WD Tap","year":"2022","unstructured":"Tap WD, Pollack S, Carter JD, Heggen C, McKinnon KE. Quality care for patients with tenosynovial giant cell tumor: a multidisciplinary quality improvement initiative. J Clin Oncol. 2022;40:56\u201356.","journal-title":"J Clin Oncol"},{"key":"3725_CR31","doi-asserted-by":"publisher","first-page":"11500","DOI":"10.1200\/JCO.2025.43.16_suppl.11500","volume":"43","author":"X Niu","year":"2025","unstructured":"Niu X, Ravi V, Martin Broto J, Zhou Y, Abdul Razak AR, Saleh R, et al. Pimicotinib in tenosynovial giant cell tumor (TGCT): efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study. J Clin Oncol. 2025;43:11500.","journal-title":"J Clin Oncol"},{"key":"3725_CR32","unstructured":"ClinicalTrials.gov. Study of Pimicotinib (ABSK021) for tenosynovial giant cell tumor (MANEUVER). 2024 [cited 2024 Oct 24]. https:\/\/clinicaltrials.gov\/study\/NCT05804045."},{"key":"3725_CR33","doi-asserted-by":"publisher","first-page":"S1340","DOI":"10.1016\/j.annonc.2025.08.3301","volume":"36","author":"X Niu","year":"2025","unstructured":"Niu X, Ravi V, Martin Broto J, Zhou Y, Razak A, Saleh R, et al. 2690MO Extended efficacy and safety from the Phase 3 MANEUVER trial of pimicotinib in patients with tenosynovial giant cell tumour (TGCT). Ann Oncol. 2025;36:S1340\u20131.","journal-title":"Ann Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03725-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03725-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03725-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:03:32Z","timestamp":1794254612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03725-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3725"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03725-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dale Shepard: Honorarium for educational presentations from Springworks, Deciphera, and Aadi; advisory boards with Springworks, Parabilis, Ipsen, Deciphera, Daiichi Sankyo, and Bayer; and institutional research funding as site principal investigator from Aadi, Cogent, Compugen, Deciphera, Eli Lilly, Inhibrx, Kinnate, Loxo, Novartis, NucMito, PMV Pharma, Pfizer, Polaris, Prelude, and Rain Therapeutics. Sydney Stern: No relevant disclosures. Nicholas M. Bernthal: Consulting\/Advisory boards with Deciphera, Daiichi Sankyo, and EMD Serono. Research support from Zimmer Biomet, NIH, MSTS, OREF, and DOD.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}